

Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 8, 2021 /PRNewswire/ -- [Viracta](#) Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021. The Company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Wednesday, April 14,
Date: 2021
Time: 3:45 PM ET
Format: Corporate presentation

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:

Joyce Allaire

LifeSci Advisors

jallaire@lifesciadvisors.com

(212) 915-2569

Company Contact:

Dan Chevallard

Chief Operating Officer and Chief Financial Officer

dchevallard@viracta.com

(858) 771-4193

SOURCE Viracta

<https://viracta.investorroom.com/2021-04-08-Viracta-Therapeutics-to-Present-at-the-20th-Annual-Needham-Virtual-Healthcare-Conference>